Description

Over 80,000 persons in the US died from an opioid overdose in 2021, reflecting a dramatic increase from 68,630 deaths in 2020. There are effective medications to treat OUD, but they are highly underutilized. The presenters will discuss the pharmacology of buprenorphine, methadone and naltrexone, the benefits and risks of these treatment options, and the ramifications of the recent removal of the X-waiver. A pain management expert will illustrate the use of these medications with two case studies.

Learning Objectives:

1.      Review the pharmacologic basics, advantages, and disadvantages of methadone, buprenorphine, naltrexone, and adjunct therapies in the treatment of opioid use disorder (OUD)

2.      Discuss recent health policy trends regarding the pharmacologic treatment of OUD.

3.      Illustrate pharmacologic OUD treatment options through real-world case study presentations.

 Presenters:

 Dr. Janet Selway, DNSc, CRNP, FAANP, a certified adult-gerontology and pediatric primary care nurse practitioner, is an associate professor and specialty director for the University of Maryland School of Nursing (UMSON) adult-gerontology primary care nurse practitioner Doctor of Nursing Practice program. She earned the Doctor of Nursing Science degree at the Johns Hopkins University School of Nursing. Dr. Selway has held nursing faculty positions at several universities over the past 30 years most recently as a tenured associate professor and associate dean for the MSN programs at the Catholic University of America Conway School of Nursing, where she worked on several grants. She currently practices at a grant-funded nurse-led clinic in W. Baltimore. Dr. Selway is a past president of state and national NP associations, serves as the current Vice Chair/Treasurer of the American Association of Nurse Practitioners (AANP) Political Action Committee, and is an active member of the legislative committee of the Nurse Practitioner Association of Maryland. In 2014, the AANP inducted her as a Fellow.

References:

• 1.     National Institute on Drug Abuse. (2021, December 2). Medications to treat opioid use disorder research report. https://nida.nih.gov/publications/research-reports/medications-to-treat-opioid-addiction/overview
• 2.     Substance Abuse and Mental Health Services Administration. (July 2021). TIP 63: Medications for opioid use disorder. https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document/PEP21-02-01-002
• 3.     Substance Abuse and Mental Health Services Administration (SAMHSA). (2023, April 25).

Removal of DATA waiver (X waiver) requirement. https://www.samhsa.gov/medications-substance-use-disorders/removal-data-waiver-requirement

Disclaimer: District of Colombia Psychological Association is approved by the American Psychological Association to sponsor continuing education for psychologists. DCPA maintains responsibility for this program and its content. There is no conflict of interest or commercial support for this program.